XBiotech Inc. (XBIT)

NASDAQ: XBIT · IEX Real-Time Price · USD
6.56
+0.10 (1.63%)
Feb 27, 2024, 9:47 AM EST - Market open
1.63%
Market Cap 197.23M
Revenue (ttm) 300,000
Net Income (ttm) -23.13M
Shares Out 30.44M
EPS (ttm) -0.76
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 7,743
Open 6.58
Previous Close 6.45
Day's Range 6.56 - 6.58
52-Week Range 3.05 - 7.24
Beta 1.38
Analysts n/a
Price Target n/a
Earnings Date Mar 13, 2024

About XBIT

XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation. The company was inco... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Apr 15, 2015
Employees 85
Stock Exchange NASDAQ
Ticker Symbol XBIT
Full Company Profile

Financial Performance

In 2022, XBiotech's revenue was $4.01 million, a decrease of -78.20% compared to the previous year's $18.39 million. Losses were -$32.90 million, 88.9% more than in 2021.

Financial Statements

News

XBiotech to Begin Constructing New R&D Facility on its 48-acre Campus

AUSTIN, Texas, Jan. 04, 2024 (GLOBE NEWSWIRE) -- XBiotech Inc. today announced that it plans to expand it's campus headquarters with the construction of a new, state-of-the-art research and developmen...

7 weeks ago - GlobeNewsWire

Dr. Alan Kivitz to Chair XBiotech's Natrunix Program in Rheumatoid Arthritis

(Phase II Multicenter Study is Proceeding Well with High Anticipation) (Phase II Multicenter Study is Proceeding Well with High Anticipation)

3 months ago - GlobeNewsWire

XBiotech Announces Enrollment Completion of Phase I Clinical Trial for Hutrukin, a Novel Candidate Therapy for Stroke

AUSTIN, Texas, Sept. 26, 2023 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) Announces that Hutrukin is being developed by XBiotech as a breakthrough therapy to reduce brain injury after stroke. The...

5 months ago - GlobeNewsWire

XBiotech Announces Enrollment Completion of Phase II, Placebo Controlled, Multicenter Study for Natrunix in Pancreatic Cancer

AUSTIN, Texas, Aug. 30, 2023 (GLOBE NEWSWIRE) -- XBiotech Inc. announced today completion of enrollment of the Phase II portion of its 1-BETTER study—a Phase I/II randomized, double-blind, placebo-con...

6 months ago - GlobeNewsWire

XBiotech Announces First Patient Begins Novel Natrunix Therapy in Phase II Rheumatoid Arthritis (RA) Clinical Trial

AUSTIN, Texas, Aug. 08, 2023 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) today began treating the first patient in a phase II, double-blind, placebo-controlled, randomized clinical study to evalu...

7 months ago - GlobeNewsWire

FDA Authorizes Phase II Study for Natrunix in Rheumatoid Arthritis Patients

XBiotech Believes its Drug Candidate Natrunix Could Revolutionize Arthritis Treatment XBiotech Believes its Drug Candidate Natrunix Could Revolutionize Arthritis Treatment

10 months ago - GlobeNewsWire

XBiotech Commences Tender Offer to Purchase up to $80,000,000 Worth of Its Shares

AUSTIN, Texas, May 17, 2023 (GLOBE NEWSWIRE) -- Xbiotech Inc. (NASDAQ: XBIT) (“Xbiotech”) announced today that it commenced a “modified Dutch auction” issuer tender offer to purchase up to $80,000,000...

10 months ago - GlobeNewsWire

XBiotech Announces First Subject Enrollment in Phase I Clinical Trial for Hutrukin, a Novel Candidate Therapy for Stroke

Hutrukin, A Therapy Discovered and Manufactured at XBiotech, Is Aimed to Reduce Brain Injury after Stroke Hutrukin, A Therapy Discovered and Manufactured at XBiotech, Is Aimed to Reduce Brain Injury a...

11 months ago - GlobeNewsWire

XBiotech Announces First Patient Enrolled into the French National Cancer Institute (INCA) Sponsored Phase I/II/III Clinical Study for Natrunix™ Therapy for Colorectal Cancer

INCA funded Phase I/II/III Study for Natrunix in Combination with Trifluridine/Tipiracil, the TASKIN Study, Launches at 20 Leading Medical Centers in France INCA funded Phase I/II/III Study for Natrun...

1 year ago - GlobeNewsWire

XBiotech Announces Successful Completion of Phase I portion of Pancreatic Cancer Study

Novel Natrunix Treatment Shows Promise in Combination Chemotherapy for Treatment of Pancreatic Cancer Novel Natrunix Treatment Shows Promise in Combination Chemotherapy for Treatment of Pancreatic Can...

1 year ago - GlobeNewsWire

Why Are XBiotech Shares Trading Higher Today

The French authority has signed off XBiotech Inc's (NASDAQ: XBIT) multicenter randomized clinical study for Natrunix combined with trifluridine/tipiracil for colorectal cancer.  The French National Ca...

1 year ago - Benzinga

XBiotech Announces French National Agency (ANSM) Approval and National Cancer Institute (INSA) funding to Support Phase I/II/III Clinical Study for Natrunix™ in Combination with Trifluridine/Tipiracil (TASKIN) for Treatment of Metastatic Colorectal Cancer

ANSM approves NATRUNIX for INSA funded Phase-I-III Study at 20 Leading Medical Centers in France ANSM approves NATRUNIX for INSA funded Phase-I-III Study at 20 Leading Medical Centers in France

1 year ago - GlobeNewsWire

XBiotech Inks Clinical Manufacturing Deal

XBiotech Manufacturing Antibody Drug for Janssen Research & Development, LLC (Janssen), One of the Janssen Pharmaceutical Companies of Johnson & Johnson XBiotech Manufacturing Antibody Drug for Jansse...

2 years ago - GlobeNewsWire

XBiotech Announces First Patient Enrolled in Phase I Clinical Trial for Novel Arthritis Therapy Natrunix-SQ

Natrunix-SQ, A True Human Antibody Therapy Discovered and Manufactured at XBiotech, Is Aimed as a Breakthrough Treatment for Arthritic Disease Natrunix-SQ, A True Human Antibody Therapy Discovered and...

2 years ago - GlobeNewsWire

FDA Approves XBiotech's IND in Rheumatology

Launching Novel True Human Antibody Therapy Natrunix™ to Treat Rheumatology Launching Novel True Human Antibody Therapy Natrunix™ to Treat Rheumatology

2 years ago - GlobeNewsWire

XBiotech to Launch Novel Candidate Therapy for Stroke

Company Commencing Phase I/II Study to Test Safety and Efficacy of its New Drug Candidate to Reduce Brain Injury After Stroke Company Commencing Phase I/II Study to Test Safety and Efficacy of its New...

2 years ago - GlobeNewsWire

XBiotech Announces Payment of Dividend to Holders of Common Stock

Company distributed USD $75 Million to Shareholders Company distributed USD $75 Million to Shareholders

2 years ago - GlobeNewsWire

XBiotech Announces Dividend to Holders of Common Stock

AUSTIN, Texas, July 06, 2021 (GLOBE NEWSWIRE) -- XBiotech Inc.'s (NASDAQ: XBIT) (“XBiotech”) Board of Directors has declared an extraordinary cash dividend of approximately $2.50 per share, or up to a...

2 years ago - GlobeNewsWire

XBiotech Announces Receipt of $75 Million from Sale of Antibody

Company Has Now Received a Total of $750 million for Sale of Its True Human Antibody Company Has Now Received a Total of $750 million for Sale of Its True Human Antibody

2 years ago - GlobeNewsWire

XBiotech Announces First Patient Enrolled in Clinical Trial Evaluating XB2001 for the Treatment of Pancreatic Cancer

XB2001 Is a Novel Therapy that Interrupts Inflammation to Potentially Block Growth and Spread of Tumors and to Reduce Toxicity of Chemotherapy Treatment XB2001 Is a Novel Therapy that Interrupts Infla...

2 years ago - GlobeNewsWire

XBiotech To Test New Drug Candidate Combined With Approved Treatment In Pancreatic Cancer

The FDA has signed off Phase 1/2 clinical study to evaluate XBiotech Inc's (NASDAQ: XBIT) XB2001 when added to the ONIVYDE/5-FU combination therapy for treating patients with pancreatic cancer. The Ph...

3 years ago - Benzinga

FDA Gives Go-Ahead for XBiotech's Candidate Therapy for Phase I/II Double-blind Placebo Controlled Study in Pancreatic Cancer

XBiotech's New Drug to Enter Clinical Studies in Combination Therapy for Pancreatic Cancer XBiotech's New Drug to Enter Clinical Studies in Combination Therapy for Pancreatic Cancer

3 years ago - GlobeNewsWire

Top Small-Cap Stocks for March 2021

These are the small-cap stocks with the best value, fastest growth, and most momentum for March 2021.

3 years ago - Investopedia

XBiotech Candidate True Human™ COVID-19 Therapy Found to Target Highly Infectious Emerging Strain

With New Infectious Strain Rapidly Spreading, XBiotech Establishes Data Indicating its Candidate True Human™ COVID-19 Therapy may be Effective for Treating New Mutant Strain With New Infectious Strain...

3 years ago - GlobeNewsWire

XBiotech Announces Cerebrovascular Medical Advisory Board & Development of New Stroke Therapy

Appointments Include: Chair, Clay Johnston, M.D., Ph.D. as well as Members Greg Albers, M.D. and Brett Cucchiara, M.D. Appointments Include: Chair, Clay Johnston, M.D., Ph.D. as well as Members Greg A...

3 years ago - GlobeNewsWire